Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMM:DADI'
s EV-to-EBIT Range Over the Past 10 Years
Min: -6044.32 Med: 9.34 Max: 164.34
Current: 7.28
During the past 13 years, the highest EV-to-EBIT of Dar Al Dawa Development and Investment was 164.34. The lowest was -6044.32. And the median was 9.34.
AMM:DADI's EV-to-EBIT is ranked better than 82.05% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.69
vs AMM:DADI: 7.28
Dar Al Dawa Development and Investment (AMM:DADI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dar Al Dawa Development and Investment's Enterprise Value for the quarter that ended in Mar. 2026 was JOD73.77 Mil.
Dar Al Dawa Development and Investment's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD10.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment EV-to-EBIT Related Terms
Dar Al Dawa Development and Investment EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment EV-to-EBIT Chart
Dar Al Dawa Development and Investment Annual Data
AMM:DADI vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment EV-to-EBIT vs Drug Manufacturers Industry
Dar Al Dawa Development and Investment's current Enterprise Value is JOD72.77 Mil.
Dar Al Dawa Development and Investment's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD10.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dar Al Dawa Development and Investment (AMM:DADI) has a EV-to-EBIT of 7.28 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 22% below median its historical median of 9.34. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #124 out of 691 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Dar Al Dawa Development and Investment's EV-to-EBIT too high?
Dar Al Dawa Development and Investment's current EV-to-EBIT of 7.28 is 22% below median its 10-year median of 9.34. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Dar Al Dawa Development and Investment's value of 7.28 is 53.6% below this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #124 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #124 out of 691 companies for EV-to-EBIT. This places Dar Al Dawa Development and Investment in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.69. Dar Al Dawa Development and Investment's value of 7.28 is 53.6% below this benchmark. While the company's 10-year median is 9.34 vs. the industry median of 15.69, Dar Al Dawa Development and Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current EV-to-EBIT of 7.28 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current EV-to-EBIT is 7.28, which is 22% below median its own 10-year median of 9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.11, compared to a current price of JOD1.19 — trading 7.2% above its estimated fair value. The current EV-to-EBIT is 7.28, which is 22% below median its 10-year median of 9.34 and 53.6% below the Drug Manufacturers industry median of 15.69. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current EV-to-EBIT is 7.28 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.19 is trading 7.2% above its estimated GF Value™ of JOD1.11.
GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.
Key valuation signals for AMM:DADI:
EV-to-EBIT: 7.28 (22% below median its 10-year median of 9.34)
GF Value™: JOD1.11 vs. price of JOD1.19 (7.2% above fair value)
Industry Position: 53.6% below the Drug Manufacturers median (#124 of 691)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score
Get the complete analysis for AMM:DADI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
